VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.

Redchenko I., Cappuccini F., Pollock E., Bryant RJ., Carter L., Verrill C., Hollidge J., Goodwin L., Harrop R., Romero PJ., Vigano S., Evans T., Catto J., Hamdy F., Hill AVS.

DOI

10.1200/jco.2018.36.15_suppl.3018

Type

Conference paper

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

20/05/2018

Volume

36

Pages

3018 - 3018

Permalink Original publication